有子宫内膜异位症病史女性的绝经期管理:一项系统综述
本文系统综述了有子宫内膜异位症病史女性绝经期症状管理的现有文献,检索MEDLINE、Embase、PsycINFO和CINAHL自建库至2016年6月,纳入病例报告/系列、观察性研究和临床试验。现有高质量证据稀少,仅两项随机对照试验,无法就激素替代治疗(HRT)相关风险得出确定性结论,疾病复发与恶变的绝对风险无法量化。
要点
- 有子宫内膜异位症病史的女性绝经后仍可能发生内异症病灶复发和恶变。
- HRT可能重新激活子宫内膜异位症并刺激恶变,但现有证据不足以量化风险。
- 高质量证据稀少,仅两项随机对照试验,亟需多中心随机试验或大型观察性研究。
核心结论
- 现有高质量证据稀少,无法就HRT相关风险得出确定性结论。
- 子宫内膜异位症复发与恶变的绝对风险无法量化,HRT使用对这些结局的影响尚不清楚。
- 亟需多中心随机试验或大型观察性研究为临床医生和患者提供依据。
研究设计与样本
- 系统综述,检索MEDLINE(经OVID)、Embase(经OVID)、PsycINFO(经OVID)和CINAHL(经EbscoHost)四个电子数据库,检索时间自建库至2016年6月。
- 纳入标准为有子宫内膜异位症病史的绝经期女性及更年期治疗(包括HRT或其他制剂)的研究;纳入病例报告/系列、观察性研究和临床试验。
- 排除叙述性综述、机构指南和会议摘要,以及未报告任何形式绝经期管理的研究;采用GRADE标准评估偏倚风险和质量。
主要发现
- 对接受绝经期症状治疗的女性中子宫内膜异位症复发或恶变的现有病例报告进行了汇总。
- 总结了各研究报告的常见就诊症状、潜在危险因素和结局。
- 识别出的高质量证据稀少,观察性研究很少,仅有两项随机对照试验。
临床怎么用
- 由于缺乏高质量研究,如何就绝经期症状管理向有子宫内膜异位症病史的女性提供建议仍不明确。
- 作者认为亟需多中心随机试验或大型观察性研究为临床医生和患者提供依据。
局限性
- 高质量证据稀少,观察性研究很少,仅有2项随机对照试验。
- 由于数据匮乏,无法就风险得出确定性结论。
- 子宫内膜异位症复发与恶变的绝对风险无法量化,HRT使用对这些结局的影响尚不清楚。
- 亟需多中心随机试验或大型观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometriosis is typically regarded as a premenopausal disease, resolving after natural or iatrogenic menopause due to declining oestrogen levels. Nonetheless, case reports over the years have highlighted the incidence of recurrent postmenopausal endometriosis. It is now clear that both recurrence and malignant transformation of endometriotic foci can occur in the postmenopausal period. Postmenopausal women are commonly treated with hormone replacement therapy (HRT) to treat climacteric symptoms and prevent bone loss; however, HRT may reactivate endometriosis and stimulate malignant transformation in women with a history of endometriosis. Given the uncertain risks of initiating HRT, it is difficult to determine the best menopausal management for this group of women. OBJECTIVE AND RATIONAL: The aim of this study was to systematically review the existing literature on management of menopausal symptoms in women with a history of endometriosis. We also aimed to evaluate the published literature on the risks associated with HRT in these women, and details regarding optimal formulations and timing (i.e. initiation and duration) of HRT. SEARCH METHODS: Four electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via EbscoHost) were searched from database inception until June 2016, using a combination of relevant controlled vocabulary terms and free-text terms related to 'menopause' and 'endometriosis'. Inclusion criteria were: menopausal women with a history of endometriosis and menopausal treatment including HRT or other preparations. Case reports/series, observational studies and clinical trials were included. Narrative review articles, organizational guidelines and conference abstracts were excluded, as were studies that did not report on any form of menopausal management. Articles were assessed for risk of bias and quality using GRADE criteria. OUTCOMES: We present a synthesis of the existing case reports of endometriosis recurrence or malignant transformation in women undergoing treatment for menopausal symptoms. We highlight common presenting symptoms, potential risk factors and outcomes amongst the studies. Sparse high-quality evidence was identified, with few observational studies and only two randomized controlled trials. Given this paucity of data, no definitive conclusions can be drawn concerning risk. WIDER IMPLICATIONS: Due to the lack of high-quality studies, it remains unclear how to advise women with a history of endometriosis regarding the management of menopausal symptoms. The absolute risk of disease recurrence and malignant transformation cannot be quantified, and the impact of HRT use on these outcomes is not known. Multicentre randomized trials or large observational studies are urgently needed to inform clinicians and patients alike.
引用
- Gemmell LC, Webster KE, Kirtley S, et al. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017. PMID: 28498913. doi:10.1093/humupd/dmx011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。